ALNY

143.8202.71%
YL

Yvonne L. Greenstreet

CEO & Director

Dr. Yvonne L. Greenstreet, MBA, M.D., is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. She has been a Director of Alnylam Pharmaceuticals, Inc. since October 28, 2021. She serves as Director at argenx SE since May 11, 2021 until March 3, 2022. She was President of Alnylam Pharmaceuticals, Inc. since October 1, 2020 until January 1, 2022. Dr. Greenstreet was Chief Operating Officer of Alnylam Pharmaceuticals, Inc. since September 19, 2016 until January 1, 2022 and served as its Executive Vice President since September 19, 2016 until March 2019. She is a member of the Board of Directors of The American Funds. Prior to joining Alnylam, Dr. Greenstreet most recently served as the founder and Managing Director of Highgate LLC, from January 2014 to August 2016. She served as Senior Vice President and Head of Medicines Development for the Specialty Care Business Unit at Pfizer Inc. from December 2010 to November 2013. Prior to joining Pfizer, Dr. Greenstreet served in various roles at GlaxoSmithKline from 1992 to 2010. She served as a Senior Vice President and Chief of Strategy, R&D at GlaxoSmithKline. Dr. Greenstreet was also a Member of the GlaxoSmithKline's Global Product Management Board. She served as Senior Vice President and Head of the Musculoskeletal, Inflammation Gastrointestinal & Urogenital Medicine Development Centre at GlaxoSmithKline (GSK) where she defined pipeline strategy and built a promising portfolio, successfully inlicensing several clinical stage assets as well as bringing three new significant medicines to market. She was at GlaxoSmithKine (GSK), most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK Product Management Board. Previously, Dr. Greenstreet served as Vice President and Head of European Clinical Development and Medical Affairs and as Chief Medical Officer of GSK in Europe, where she was responsible for the development and delivery of European phase II-IV clinical plans, studies and submissions. She served as Vice President and Medical Director for Pharmaceutical business in the UK. Dr. Greenstreet has Pharmaceutical Industry experience in medicines development, medical affairs and business development. Dr. Greenstreet is highly regarded for her vision and ability in identifying emerging opportunities, her expertise in drug development and her success in building highly functioning organizations. She was a Non-Executive Director at Indivior PLC since November 04, 2014 until March 31, 2019. She had been a Director of Pacira BioSciences, Inc. (formally known as Pacira Pharmaceuticals, Inc.) since March 4, 2014 until 2023. She is a member of the Discovery Council of Harvard Medical School. She is also a member of Biotechnology Industry Organization Health Section Governing Board. She was an Independent Director at Moelis & Company since February 19, 2015 until December 31, 2018. She served as a Independent Non-Executive Director of Advanced Accelerator Applications S.A. since June 2014 until May 2017. She was a Member of Strategic Advisory Board at Lupin Limited. She served as an Independent Director of Molecular Insight Pharmaceuticals, Inc. from September 2008 to January 2010. She serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and has received widespread industry recognition, including being recognized by Fast Company as one of the 100 most creative people in business in the United States in 2013 and by Fierce Biotech as one of the top ten women in Biotechnology in 2012. Dr. Greenstreet completed her medical training at the University of London Hospitals in London, United Kingdom in 1990 and received her MBChB from the University of Leeds in Leeds, United Kingdom in 1985. She studied at several London teaching hospitals including St. Thomas, St. Mary's University College and St. Bartholomews. She Obtained an M.B.A from INSEAD, France in 1991.

Positions